Outdated federal policies concerning cannabis have impeded research and prevented patients from accessing the full therapeutic potential of cannabis. The recommendation by the U.S. Department of Health and Human Services the Drug Enforcement Agency reschedule cannabis from a Schedule I to a Schedule III substance under the Controlled Substances Act is an important and necessary shift.
Made in August 2023, the recommendation has been working its way through the approval process. The DEA needs to approve it.
Donald Trump has indicated that he supports the effort to reclassify cannabis. As research scientists in neuroscience and pharmacology, we strongly support this rescheduling effort because it is a scientifically sound decision that will advance medical research on the efficacy of cannabis to improve patient care and public health.
Importantly, this does not legalize recreational use. It simply reduces the barriers to research and patients’ access to medical marijuana.
Medically useful
Schedule I substances are classified as having no accepted medical use and a high potential for abuse. This categorization places cannabis in the same regulatory category as heroin and LSD — a status that is obviously detrimental to medical progress.
Cannabis’ Schedule I status severely restricts research. Scientists must obtain approvals from multiple federal agencies, including the Drug Enforcement Administration (DEA) and the Food and Drug Administration (FDA). It restricts researchers’ access to a variety of products presently used by patients. Current restrictions limit research to a small handful of federally-approved sources.
These restrictions limit our ability to conduct the large-scale clinical trials necessary to fully understand the therapeutic potential of cannabis and any possible dangers. Rescheduling to Schedule III would alleviate many of these obstacles.
Schedule III substances are recognized as having medical use. The proposed reclassification aligns with growing scientific research supporting its medicinal benefits. Already, the majority of states accept the evidence of its medical benefits.
Improved patient care
One of the most compelling reasons for rescheduling cannabis is its potential to improve patient care. Cannabis compounds have demonstrated efficacy in managing chronic pain, chemotherapy-induced nausea and vomiting, epilepsy, and multiple sclerosis, among other conditions. Indeed, several FDA-approved drugs are derived from cannabis.
The current federal classification, however, creates disparities in access. While many states have legalized medical cannabis, the Schedule I status at the federal level creates confusion, restricts insurance coverage, and discourages healthcare providers from integrating cannabis into treatment plans. Rescheduling to Schedule III would reduce this uncertainty, enabling physicians to more confidently discuss cannabis with patients.
Pennsylvania’s medical marijuana program serves as a strong example of how state-level policies can provide relief to patients suffering from serious medical conditions. Since its implementation in 2016, the program has allowed thousands of patients with conditions such as chronic pain, cancer and PTSD to access medical cannabis.
Rescheduling cannabis would also enhance safety and quality control. Currently, the lack of federal oversight produces an environment where medical cannabis products vary widely in potency, purity, and composition. While Pennsylvania has implemented stringent quality control mechanisms and a regulated dispensary program, the same is not true for all states.
By moving cannabis to Schedule III, the FDA would have greater regulatory authority to ensure standardized dosing, proper labeling, and rigorous safety testing. This would not only improve patient outcomes but also mitigate the risks of contamination and variable product efficacy.
Justified and necessary
HHS’s recommendation to reschedule cannabis to Schedule III is a scientifically justified and necessary step that will remove barriers to research, enhance patient access to treatment and improve product safety.
By allowing researchers to do the research needed, it enables them to better serve healthcare providers and patients. By reducing the barriers to patient access, it lets more people benefit from medical marijuana.
Kent Vrana, director of the Penn State University Medical Marijuana Academic Clinical Research Center and emeritus chair of pharmacology at PSU’s College of Medicine and Dr. Wesley Raup-Konsavage, director of research for the Clinical Research Center




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.